Nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment in advanced biliary tract cancer: results of a multicentre, randomised, phase II trial

Yang Xiao, Liang Zhuang, H Cheng, Yong Dai, Mingsheng Zhang, Qiang Fu, shun fang Liu, Li Sun, Yifeng Zou, Haisheng Xu, Ping Qiu, Qiao Huang, Hong QiuResearch Square 2025 · DOI

Abstract

Background: The efficacy and safety of conventional first-line chemotherapeutic regimens for the treatment of advanced biliary tract carcinomas (ABTCs) have been unsatisfactory. Objectives: We aimed to explore alternative chemotherapeutic regimens capable of providing a better efficacy and fewer side effects. Design: Multicentre, randomised, phase II clinical trial. Methods: Eligible patients with unresectable, recurrent, or metastatic biliary system tumours diagnosed by pathology or cytology between January 2021 and November 2022 were included. The participants were randomised to either a gemcitabine-cisplatin group (GC) or an albumin-paclitaxel-cisplatin group (NC). Progression-free survival (PFS) was the primary outcome, whereas overall survival (OS), and objective response rate (ORR) were the secondary outcomes. Results: The trial enrolled 75 patients and had a median follow-up period of 11 months. The median PFS (mPFS) was 7.8 m (95% CI: 5.4–14.0 m) in the NC group, and 7.0 m (95% CI: 3.9–10.1 m) in the GC group (p=0.0034, HR=0.5136). Median OS for the NC group was 12.4 m and for the GC group was 12.1 m (p=0.4592). PFS rates at 6 and 8 months were significantly higher in the NC group. Regarding safety, the NC group demonstrated significantly lower rates of thrombocytopenia. Conclusion: Compared with the GC group, the NC group showed a significantly increased mPFS and lower haematological toxicity, suggesting paclitaxel-based regimens as a viable alternative for first-line treatment of ABTCs.

Introduction

Biliary tract cancer (BTC), encompassing gallbladder cancer and cholangiocarcinoma, is an aggressive malignancy often diagnosed at advanced stages. For over a decade, the combination of gemcitabine and cisplatin (GC) has served as the global standard for first-line therapy. However, clinical outcomes remain suboptimal, and the regimen is frequently associated with significant hematological toxicities.

This multicentre Phase II trial investigated whether replacing gemcitabine with nab-paclitaxel (an albumin-bound formulation) could improve efficacy and safety. Nab-paclitaxel utilizes albumin transport pathways to enhance drug delivery to tumor cells, potentially offering a more targeted therapeutic approach.

Methods and Patient Characteristics

The study was conducted as an open-label, randomized, phase II trial across four cancer centers in China. A total of 75 patients with unresectable, recurrent, or metastatic BTC were enrolled and randomized into two groups:

  • NC Group (n=37): Nab-paclitaxel (125 mg/m²) on days 1 and 8 plus Cisplatin (25 mg/m²) on days 1–3.
  • GC Group (n=38): Gemcitabine (1000 mg/m²) on days 1 and 8 plus Cisplatin (25 mg/m²) on days 1–3.

Treatments were administered in 21-day cycles for up to six cycles, followed by S-1 maintenance therapy. The primary endpoint was progression-free survival (PFS).

Baseline clinical and pathological characteristics of the study participants.

As shown in the baseline data, the groups were well-balanced regarding age, sex, and tumor primary site, with the majority of patients in both cohorts presenting with liver metastasis at enrollment.

Results

Efficacy

The NC regimen demonstrated a statistically significant improvement in the primary endpoint. The median PFS was 7.8 months for the NC group versus 7.0 months for the GC group ($p=0.0034$; HR=0.5136). The 6-month PFS rate was also notably higher in the NC group (70.83% vs. 48.24%).

Despite the improvement in PFS, median overall survival (OS) did not differ significantly between the groups, reaching approximately 12 months for both (12.4m for NC vs. 12.1m for GC, $p=0.4592$). This suggests that while NC is more effective at delaying initial disease progression, subsequent lines of therapy or disease biology may influence long-term survival outcomes similarly.

Safety Profile

The study revealed a distinct shift in the toxicity profile between the two regimens:

  • Hematological Toxicity: The NC group experienced significantly lower rates of thrombocytopenia (low platelet counts) compared to the GC group (32.4% vs. 50.0%, $p=0.041$).
  • Neurological Toxicity: Conversely, sensory neuropathy was more prevalent in the NC group (62.1% vs. 36.8%, $p=0.028$), a known side effect of taxane-based therapies. These symptoms were generally manageable and improved post-treatment.

Discussion and Conclusion

The findings suggest that the NC regimen is a potent alternative to the standard GC combination for advanced biliary tract cancer. By leveraging the tumor-targeting properties of nab-paclitaxel, clinicians can achieve superior progression-free survival with a reduced burden of bone marrow suppression.

However, the study faced limitations, including a relatively small sample size and early termination due to the emergence of immunotherapy (PD-L1 inhibitors) as a new standard of care. Future research will focus on integrating these chemotherapy backbones with immune checkpoint inhibitors to determine if the PFS benefits of nab-paclitaxel can be translated into improved overall survival for patients with BTC.

Registration: ClinicalTrials.gov NCT04692051.

Summary updated

Abstract

<title>Abstract</title> Background: the efficacy and safety of conventional first-line chemotherapeutic regimens for the treatment of advanced biliary tract carcinomas (ABTCs) have been unsatisfactory. Objectives: We aimed to explore alternative chemotherapeutic regimens capable of providing a better efficacy and fewer side effects. Design: Multicentre, randomised, phase II clinical trial <bold>Methods</bold>: Eligible patients with unresectable, recurrent, or metastatic biliary system tumours diagnosed by pathology or cytology between January 2021 and November 2022 were included. The participants were randomised to either a gemcitabine-cisplatin group (GC) or an albumin-paclitaxel-cisplatin group (NC). Progression-free survival (PFS) was the primary outcome, whereas overall survival (OS), and objective response rate (ORR) were the secondary outcomes. <bold>Results</bold>: The trial enrolled 75 patients and had a median follow-up period of 11 months. The median PFS (mPFS) was 7.8 m (95% confidence interval [CI]: 5.4–14.0 m) in the NC group, and 7.0 m (95%CI: 3.9–10.1 m) in the GC group (p=0.0034, hazard ratio [HR]=0.5136, 95%CI: 0.3136–0.8411). Median OS for the NC group was 12.4 m (95%CI: 7.3–22.3 m) and for the GC group was 12.1 m (95%CI: 6.7–20.7 m), with no significant differences (p=0.4592, HR=0.811, 95%CI: 0.463–1.442). PFS rates at 6 and 8 months were 48.24% vs. 70.8% and 8.51% vs. 32.0% for the NC and the GC group, respectively (p &lt; 0.05). Regarding safety, although patients from both groups experienced thrombocytopenia, those in the NC group demonstrated significantly lower rates (p &lt; 0.05). Conclusion: Compared with the GC group, the NC group showed a significantly increased mPFS, in addition to higher PFS rates at 6 and 8 months. Furthermore, the NC group showed lower haematological toxicity. This suggests that paclitaxel-based regimens may be a viable alternative for first-line treatment of ABTCs. Registration: Clinical Trials.gov identifiers: NCT04692051. Registered October 31, 2018 (Web Links -https://www.chictr.org.cn/showproj.html?proj=38440)
BibTeX
@inproceedings{xiao2025nab,
  author = {Yang Xiao and Liang Zhuang and H Cheng and Yong Dai and Mingsheng Zhang and Qiang Fu and shun fang Liu and Li Sun and Yifeng Zou and Haisheng Xu and Ping Qiu and Qiao Huang and Hong Qiu},
  title = {{Nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment in advanced biliary tract cancer: results of a multicentre, randomised, phase II trial}},
  booktitle = {Research Square},
  year = {2025},
  doi = {10.21203/rs.3.rs-5762910/v1},
}

Loading related content...

Figure